Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.

ABSTRACT:

Background

Addition of trastuzumab to first-line palliative chemotherapy in gastroesophageal cancer patients with HER2 overexpression has shown to improve survival. Real-world data on HER2 assessment and administration of trastuzumab are lacking. The aim of this study was to assess HER2 testing, trastuzumab administration, and overall survival (OS) in a nationwide cohort of metastatic gastroesophageal cancer patients.

Methods

Data of patients with synchronous metastatic gastroesophageal adenocarcinoma diagnosed in 2010-2016 that received palliative systemic treatment (n = 2846) were collected from the Netherlands Cancer Registry and Dutch Pathology Registry. The ToGA trial criteria were used to determine HER2 overexpression. Proportions of HER2 tested patients were analyzed

SUBMITTER: Dijksterhuis WPM 

PROVIDER: S-EPMC7305095 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature